Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the year to this March 31st.